Who is Dr. Marschall S. Runge and why is he joining the board?

Dr. Marschall S. Runge is the Executive Dean of the School of Medicine at the University of North Carolina at Chapel Hill. He has been elected to Eli Lilly's Board of Directors to bring his extensive experience in medicine and scientific leadership, particularly to the Science and Technology Committee.

What committees will Dr. Runge be serving on, and what does this imply for Lilly?

Dr. Runge will serve on the Science and Technology Committee and the Public Policy and Compliance Committee. His involvement in the Science and Technology Committee suggests a continued emphasis on innovation and research & development, while his role in Public Policy and Compliance highlights the company's commitment to strong governance and regulatory adherence.

When will Dr. Runge's directorship become official and when will shareholders vote on his position?

Dr. Runge's appointment is effective September 1, 2013. He will serve under an interim election and will stand for formal election by Eli Lilly shareholders at the company's annual meeting in May of 2013 (this appears to be a typo in the original filing, likely meant for May 2014).

Are there any financial arrangements or conflicts of interest associated with Dr. Runge's appointment?

The filing states there are no arrangements with other parties for his selection, nor is he involved in any transactions subject to specific SEC regulations (Section 404(a) of Regulation S-K) with the company. He will participate in the standard Director's compensation program as outlined in the company's 2013 Proxy Statement.

LLY 8-K: Leadership Changes

Summary

Eli Lilly and Company (LLY) announced on August 28, 2013, a significant addition to its Board of Directors with the election of Dr. Marschall S. Runge, effective September 1, 2013. Dr. Runge, a respected figure in academia as the Executive Dean of the School of Medicine at the University of North Carolina at Chapel Hill, brings a wealth of scientific and medical expertise to the board. His appointment is particularly noteworthy for his intended service on the Science and Technology Committee and the Public Policy and Compliance Committee. This strategic addition suggests a continued focus by Lilly on leveraging cutting-edge research and development, as well as maintaining robust ethical and regulatory standards. Investors should view this as a positive signal regarding the company's commitment to innovation and responsible corporate governance.

Key Highlights

1Eli Lilly & Co. appointed Dr. Marschall S. Runge to its Board of Directors, effective September 1, 2013.
2Dr. Runge's expertise is from his role as Executive Dean of the School of Medicine at the University of North Carolina at Chapel Hill.
3Dr. Runge will serve on the Science and Technology Committee, indicating a focus on R&D.
4He will also join the Public Policy and Compliance Committee, reinforcing the company's commitment to governance.
5Dr. Runge's appointment is subject to interim election and will be presented for shareholder approval at the next annual meeting.
6There are no disclosed related-party transactions or arrangements concerning Dr. Runge's appointment.

ELI LILLY & Co 8-K Report, Executive Changes (Aug 28, 2013)

Summary

Key Highlights

Frequently Asked Questions